Every parent who’s sat across from a pediatrician holding a fresh ADHD diagnosis has heard some version of the same line: “We usually start with a stimulant.” Maybe there’s a mention of a non-stimulant as a fallback, for the anxious kid or the family nervous about a controlled substance. But nobody hands you data comparing the two head-to-head. There isn’t any. Not real trial data, anyway, just decades of individual clinician judgment dressed up as a standard of care.

That changes this month. Enrollment opened in September 2026 for a $16.7 million, PCORI-funded national trial, the largest clinical trial contract in SUNY Upstate Medical University’s history, built to answer exactly that question in real kids, under real-world conditions, for the first time.

TL;DR

Question	Answer
What’s being tested?	Whether starting ADHD treatment with a stimulant or a non-stimulant leads to better outcomes
Who’s running it?	SUNY Upstate Medical University, funded by PCORI
How big?	~1,000 children and adolescents, ages 6-16, at 7 clinical sites across the US
How much funding?	$16.7 million — the largest clinical trial contract in Upstate’s history
Who’s leading it?	Stephen Faraone, PhD (SUNY Upstate) and Jeffrey Newcorn, MD (Icahn School of Medicine at Mount Sinai)
When does it open?	September 2026
Does it include comorbidities?	Yes — kids with anxiety, depression, learning differences, and autism are explicitly included
Our take	This is the study that should have existed before “start with a stimulant” became the default. It won’t give you an answer this year, but it’s finally asking the right question.

---

What This Trial Is Actually Testing

Kids and teens ages 6 to 16 will be randomly assigned to start ADHD treatment with either a stimulant or a non-stimulant medication. Then researchers track them for a full 12 months: functioning at home and school, side effects, treatment satisfaction, and how often families end up switching medications anyway.

That last measure matters more than it sounds like it should. A strategy that “works” on paper but gets abandoned by month three because the side effects were unbearable isn’t actually the better strategy. This trial is built to catch that.

It’s a comparative-effectiveness trial, not a drug trial. Nobody’s testing whether stimulants or non-stimulants work; both classes are already FDA-approved and both already have research behind them individually. What’s never existed is a well-powered study comparing the strategy of leading with one class over the other, across a population that looks like the kids actually walking into pediatric offices.

Why This Question Has Never Been Answered

Current clinical guidelines lean hard toward stimulants as the default first-line treatment. Stimulants work well for a lot of kids, and there’s a huge body of evidence behind them individually. But “works well for a lot of kids” isn’t the same as “is the right first choice for this kid,” and guidelines built on individual drug trials were never designed to answer that.

Faraone and Newcorn made this exact argument in a Nature Mental Health commentary ahead of the trial, questioning whether the evidence really supports treating stimulants as the presumptive first choice for every child rather than weighing stimulants and non-stimulants more evenly from the start. They’ve been explicit that this isn’t an anti-stimulant position. It’s a “we don’t actually know” position, and a trial is how you stop guessing.

Some of that uncertainty already shows up elsewhere in ADHD medication research. We’ve covered stimulant shortages forcing families into fallback plans they never chose, and the Lancet dosing research showing most patients on stimulants are already under- or over-dosed relative to what actually works for them. None of that tells a family whether a non-stimulant might have been the better starting point in the first place. This trial is the first attempt to fill that specific gap.

What Is PCORI?

PCORI (the Patient-Centered Outcomes Research Institute) is an independent, nonprofit research funder created by Congress to produce evidence patients and clinicians can actually use in real decisions, not just evidence that proves a drug beats a placebo. It funds comparative-effectiveness research: studies that pit real-world treatment strategies against each other, head-to-head, the way this ADHD trial does.

Who’s Included, and Why That’s the Bigger Story

Most ADHD drug trials exclude the messiest, most common real-world cases: kids with anxiety, depression, learning disabilities, or autism layered on top of ADHD. That’s how you get a clean dataset. It’s also how you get findings that don’t apply to a huge share of the kids actually sitting in a psychiatrist’s waiting room.

This trial does the opposite. Kids with co-occurring anxiety, depression, learning differences, and autism spectrum conditions are explicitly included, specifically to reflect the population clinicians actually see. That’s a meaningfully different design choice than most pharma-funded trials make, and it’s the detail most coverage of this study is going to bury.

We’ve written before about how ADHD and autism together break the assumptions built into most single-diagnosis systems: tools, treatment plans, even research designs default to one condition at a time, and kids with both get advice that only half-applies. A medication trial that finally includes that population instead of screening it out is worth noticing on its own.

What Happens During the 12 Months?

For a family enrolled in the trial, the shape of it looks roughly like this:

1. Randomization. The child is assigned to start with either a stimulant or a non-stimulant, not chosen by the family or clinician, which is exactly what makes the comparison scientifically meaningful.
2. Ongoing clinical care. Kids keep seeing their care team and get their medication managed as they normally would, just within the trial’s tracking structure.
3. Repeated check-ins. Functioning, side effects, and satisfaction get measured at multiple points across the year, not just at the start and end.
4. Tracking medication changes. If a family switches strategies mid-trial (because the first approach isn’t working), that switch itself becomes data, not a dropout.
5. Final comparison at 12 months. Outcomes across the stimulant-first and non-stimulant-first groups get compared to see which strategy produced better real-world results.

Upstate itself isn’t one of the enrolling clinical sites. It’s serving as the trial’s data management and analysis center, the unglamorous infrastructure work that makes a seven-site national study analyzable as one dataset instead of seven disconnected ones.

So Should You Start Your Kid on a Stimulant or a Non-Stimulant?

Right now, that’s still your prescriber’s judgment call, not a question with a data-backed answer. That’s the honest, slightly unsatisfying truth this whole trial exists to fix.

What’s changed is that “why did we start with this one” is about to become an answerable question instead of a shrug. If your child was just diagnosed and you’re facing that decision now, in September 2026, you’re making it with the same incomplete information every parent before you had. The trial results won’t publish for years. Randomization plus a 12-month follow-up plus analysis time is a multi-year timeline, and PCORI hasn’t published an expected completion date yet.

That’s not a reason to panic about a decision you have to make this fall. Stimulants and non-stimulants are both FDA-approved, both studied individually, and both help a lot of kids. It’s a reason to ask your prescriber directly why they’re recommending the order they’re recommending, and to know that “because that’s just what we usually do first” is a weaker answer than it used to sound like.

What This Trial Won’t Tell You

It won’t tell you which medication is right for your kid. Comparative-effectiveness research at this scale produces population-level findings — which strategy works better on average, across a large and varied group. It’s not built to replace the trial-and-error process of finding the right medication and dose for one specific child, the way the Lancet dosing study already documented is often a months-long process even after the drug class is chosen.

It also won’t move fast. Enrollment is only opening now. A family enrolling this month is contributing to a dataset that helps kids diagnosed years from now, not necessarily reshaping their own care mid-trial. That’s how comparative-effectiveness research works, and it’s worth saying plainly instead of overselling what a September 2026 enrollment date actually changes today.

And it’s one trial. Even a well-designed, well-funded, 1,000-child study doesn’t settle a clinical question on its own. It’s the first real data point in a conversation that’s operated on guesswork for decades. We’ve seen the same pattern with the BMJ’s 200-study treatment review: more evidence changes the confidence behind a recommendation, but it rarely produces a single clean answer overnight.

Our Take

The headline number here is $16.7 million, and it’s an easy detail to lead with. The more important part is the design: seven sites, comorbidities folded in instead of screened out, outcomes tracked beyond just “did symptoms improve.” This is a trial designed by people who clearly understand that a stimulant-first default built on individual drug studies was never actually tested as a strategy against the alternative.

It also lands next to a broader pattern this year of ADHD care finally getting formal structure it never had. We covered APSARD’s first-ever US adult ADHD guidelines entering final review just weeks before this trial opened enrollment — another instance of a field writing down, on purpose, something that had only ever existed as scattered individual judgment. Adult diagnosis criteria one month, pediatric medication sequencing the next. Neither fixes anything by itself. Both are the same underlying problem finally getting real attention: too much of ADHD care has run on “this is just what we do,” with no data behind the “why.”

If your child is starting treatment this fall, this trial won’t change the conversation in your pediatrician’s office today. But in a few years, “should we start with a stimulant or a non-stimulant” might finally have an answer better than a shrug and forty years of habit.

---

Not medical advice. If your child has been diagnosed with ADHD, medication decisions should be made with a licensed prescriber who knows their full history. This post covers a research trial, not treatment guidance.